2021.07.09
I-Mab today announced the signing of two new collaborations with emerging biotech companies in China to strengthen its next-generation innovation pipeline.
2021.07.01
I-Mab today announced multiple advancements in its 4-1BB bispecific antibody portfolio.
2021.06.30
I-Mab today announced that it was ranked among the top companies by leading global financial publication Institutional Investor in both the “Honored Companies” and “Best CFO” categories, according to its 2021 All-Asia Executive Team survey.
2021.06.29
I-Mab today announced its participation in the following conference in July.
2021.06.25
I-Mab today announced that the Center for Drug Evaluation of the China NMPA has approved the IND application to initiate a phase 1b trial of felzartamab, a CD38 antibody, in patients with SLE.
2021.06.21
I-Mab today announced the appointment of Andrew Zhu, MD, PhD, to the Company’s Scientific Advisory Board.
2021.06.02
I-Mab today announced that it will hold a call with investors on Monday, June 7 at 8:00 a.m. ET to provide an in-depth clinical data analysis of its U.S. phase 1 study of uliledlimab in combination with atezolizumab in patients with advanced cancers.
2021.06.01
I-Mab today announced that Dr. Ruyi He and Professor Rong Shao have been elected as members of the Company’s board of directors.
2021.05.27
I-Mab today announced its participation in the following conferences in June.
2021.05.19
I-Mab today announced that an abstract detailing clinical data from its U.S. phase 1 study of uliledlimab in combination with atezolizumab in patients with advanced cancer will be presented at the 2021 ASCO Annual Meeting, taking place June 4-8, 2021.